Temasek and CVC Capital Partners Acquire Majority Stake in Alvogen

Singapore’s Temasek Holdings and private equity giant CVC Capital Partners are purchasing a controlling interest in New Jersey-based Alvogen, a generic drugs pharmaceutical company. The transaction values Alvogen at US$ 2 billion. Increasingly, institutional investors are spending more capital on healthcare company, specifically pharmaceutical companies. In Portuguese, alvo means target or goal.

Subscribers Only: December 2014 – Direct Healthcare Investments by Sovereign Wealth Funds

[ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute
institutional investor investment mandates